Ayşe Demirci

Ayşe Demirci

Auto-generated profile, based on publicly available information

Ayşe Demirci

Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2013 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
ADAyşe Demirci
Ayşe Demirci
ÖBÖznur Bal
Öznur Bal
ADAyşe Durnali
Ayşe Durnali
AEAhmet Ş Ekinci
Ahmet Ş Ekinci
OEOnur Eşbah
Onur Eşbah
BÖBerna Öksüzoğlu
Berna Öksüzoğlu
Introduction: Sunitinib is an oral inhibitor of tyrosine kinase that was used for the treatment of mRCC. The general side effects are fatigue, asthenia, diarrhea, mucositis, nausea, vomiting, skin changes, hypertension, hypothyroidism and hematologic side effects. In addition, sunitinib-induced hypoglycemia has also been reported. There are limited number of case reports related to sunitinib-induced hypoglycemia. Case presentation: In this case report, we have presented a patient with type 2 diabetes mellitus (DM) with emerging severe hypoglycemia after sunitinib treatment. It was shown that blood glucose levels were normalized two weeks after the interruption of sunitinib. Conclusion: Although the underlying mechanism of sunitinib-induced hypoglycemia is not completely understood, sunitinib can be regarded to have an antidiabetic effect. In the literature, there are some reports about sunitinib/other TKI induced hypoglycemia; however, life threatening hypoglycemia is rare. There is no case report of severe hypoglycemia due to imatinib; however, there are two case reports with severe hypoglycemia due to sunitinib treatment. Symptomatic hypoglycemic episodes due to sunitinib may lead to hospital admission. Diabetic patients may develop severe hypoglycaemia and it should be kept in mind that the discontinuation of antihyperglycemic treatment may be required. Therefore, blood glucose levels should be closely monitored in diabetic patients with mRCC during sunitinib therapy.

8 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ADAyşe Demirci
Ayşe Demirci
CBCemil Bilir
Cemil Bilir
BGBurcu Gülbağcı
Burcu Gülbağcı
İHİlhan Hacıbekiroğlu
İlhan Hacıbekiroğlu
İBİbrahim V. Bayoğlu
İbrahim V. Bayoğlu
BÖBerna Öksüzoğlu
Berna Öksüzoğlu
To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of ≥ 50% was higher in the E group (p = 0.020). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p < 0.001 and p = 0.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p = 0.010 and p = 0.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group (p = 0.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being ≥ 75 years and a PSA decline of ≥ 50% while there was no factor affecting OS. With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.

18 March 2015
Verified
Journal Article
Closed access
OBOznur Bal
Oznur Bal
UAUlku Yalcintas Arslan
Ulku Yalcintas Arslan
ADAyse Durnali
Ayse Durnali
UUUmmugul Uyetrk
Ummugul Uyetrk
ADAyse Demirci
Ayse Demirci
BOBerna Oksuzoglu
Berna Oksuzoglu

27 June 2014
Verified
Journal Article
Closed access
UUUmmugul Uyeturk
Ummugul Uyeturk
ITIbrahim Turker
Ibrahim Turker
OBOznur Bal
Oznur Bal
ADAyse Demirci
Ayse Demirci
OSOzlem Uysal Sonmez
Ozlem Uysal Sonmez
BOBerna Oksuzoglu
Berna Oksuzoglu

21 April 2017 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ADAyşe Demirci
Ayşe Demirci
NANecati Alkış
Necati Alkış
FDFaysal Dane
Faysal Dane
ADAyşe Durnalı
Ayşe Durnalı
ÖYÖmer Kamil Yazıcı
Ömer Kamil Yazıcı
MGMahmut Gümüş
Mahmut Gümüş

30 December 2020 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
İAİrem Akdemir
İrem Akdemir
ADAyşe Demirci
Ayşe Demirci
GCGule Cinar
Gule Cinar
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen